FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2010499248> ?p ?o ?g. }

• W2010499248 endingPage "431" @default.
• W2010499248 startingPage "425" @default.
• W2010499248 abstract "Surgery has always been considered to be the primary treatment in patients with neuroendocrine gut and pancreatic tumors, but a significant number of patients present liver metastases already at the first visit. There is obviously a need for effective medical treatment and in the present paper we report our experience of treatment with chemotherapy, the somatostatin analogue SMS 201-995 and interferons. In 30 patients with malignant endocrine pancreatic tumors, chemotherapy including streptozotocin plus 5-fluorouracil had an objective response rate of 63 % with a mean duration of the objective response of 17.4 months. There was a difference between clinically functioning and nonfunctioning tumors, which had objective response rates of 68% and 50% and mean response duration of 21 and 9.4 months respectively. The new somatostatin analogue SMS 201-995 was used in 10 patients giving an objective response rate of 40% with a mean duration of 13.5 months. In a series of 22 patients treated with human leukocyte interferon, an objective response rate of 77% was obtained with a mean duration of 8.5 months. A combination of streptozotocin plus 5-fluorouracil gave an objective response rate of 10% with a mean duration of 2.7 months among 31 patients with midgut carcinoid tumors. The somatostatin analogue SMS 201-995, tested in 22 patients with carcinoid tumors, gave an objective response rate of 28 % with a mean duration of 18.5 months. Interferon has been tried in three separate studies. The first study, including 36 patients with malignant carcinoid tumors treated with human leukocyte interferon, showed an objective response rate of 47% with a mean duration of 34 months. In a randomized controlled study, where human leukocyte interferon was compared with streptozotocin plus 5-fluorouracil including 10 patients in each arm, no objective response was obtained during the six months' observation in the group of patients receiving chemotherapy, whereas 50% responded in the interferon-treated group. In the third study, IFN-aL2b or IntronA was tested in 20 patients with malignant carcinoid tumors and gave an objective response rate of 55 % during a six-month observation period. With regard to these data chemotherapy and interferons seem to be equally potent in the treatment of malignant endocrine pancreatic tumors, whereas interferons seem to be superior to both chemotherapy and the somatostatin analogue SMS 201-995 in malignant carcinoid tumors. The somatostatin analogue has proved to be particularly useful in the treatment of patients with severe hormone-related clinical symptoms and in the perioperative period. The analogue can be combined with interferon or chemotherapy for controlling severe clinical symptoms." @default.
• W2010499248 created "2016-06-24" @default.
• W2010499248 creator A5009862688 @default.
• W2010499248 creator A5040645190 @default.
• W2010499248 date "1989-01-01" @default.
• W2010499248 modified "2023-09-30" @default.
• W2010499248 title "Medical Treatment of Neuroendocrine Gut and Pancreatic Tumors" @default.
• W2010499248 cites W1922426788 @default.
• W2010499248 cites W1965478841 @default.
• W2010499248 cites W1966669049 @default.
• W2010499248 cites W1967612457 @default.
• W2010499248 cites W1995007604 @default.
• W2010499248 cites W2005592453 @default.
• W2010499248 cites W2009934924 @default.
• W2010499248 cites W2010346811 @default.
• W2010499248 cites W2032551896 @default.
• W2010499248 cites W2040511471 @default.
• W2010499248 cites W2057536718 @default.
• W2010499248 cites W2058650437 @default.
• W2010499248 cites W2063862702 @default.
• W2010499248 cites W2096864266 @default.
• W2010499248 cites W2161138887 @default.
• W2010499248 cites W2331204701 @default.
• W2010499248 cites W2337135362 @default.
• W2010499248 cites W2340185896 @default.
• W2010499248 doi "https://doi.org/10.3109/02841868909111217" @default.
• W2010499248 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2472826" @default.
• W2010499248 hasPublicationYear "1989" @default.
• W2010499248 type Work @default.
• W2010499248 sameAs 2010499248 @default.
• W2010499248 citedByCount "64" @default.
• W2010499248 countsByYear W20104992482013 @default.
• W2010499248 countsByYear W20104992482014 @default.
• W2010499248 countsByYear W20104992482020 @default.
• W2010499248 countsByYear W20104992482023 @default.
• W2010499248 crossrefType "journal-article" @default.
• W2010499248 hasAuthorship W2010499248A5009862688 @default.
• W2010499248 hasAuthorship W2010499248A5040645190 @default.
• W2010499248 hasBestOaLocation W20104992481 @default.
• W2010499248 hasConcept C121608353 @default.
• W2010499248 hasConcept C126322002 @default.
• W2010499248 hasConcept C141071460 @default.
• W2010499248 hasConcept C2776297358 @default.
• W2010499248 hasConcept C2776694085 @default.
• W2010499248 hasConcept C2777701055 @default.
• W2010499248 hasConcept C2779066768 @default.
• W2010499248 hasConcept C2780456651 @default.
• W2010499248 hasConcept C2781025020 @default.
• W2010499248 hasConcept C2781151469 @default.
• W2010499248 hasConcept C2781228144 @default.
• W2010499248 hasConcept C46699223 @default.
• W2010499248 hasConcept C71315377 @default.
• W2010499248 hasConcept C71924100 @default.
• W2010499248 hasConcept C90924648 @default.
• W2010499248 hasConceptScore W2010499248C121608353 @default.
• W2010499248 hasConceptScore W2010499248C126322002 @default.
• W2010499248 hasConceptScore W2010499248C141071460 @default.
• W2010499248 hasConceptScore W2010499248C2776297358 @default.
• W2010499248 hasConceptScore W2010499248C2776694085 @default.
• W2010499248 hasConceptScore W2010499248C2777701055 @default.
• W2010499248 hasConceptScore W2010499248C2779066768 @default.
• W2010499248 hasConceptScore W2010499248C2780456651 @default.
• W2010499248 hasConceptScore W2010499248C2781025020 @default.
• W2010499248 hasConceptScore W2010499248C2781151469 @default.
• W2010499248 hasConceptScore W2010499248C2781228144 @default.
• W2010499248 hasConceptScore W2010499248C46699223 @default.
• W2010499248 hasConceptScore W2010499248C71315377 @default.
• W2010499248 hasConceptScore W2010499248C71924100 @default.
• W2010499248 hasConceptScore W2010499248C90924648 @default.
• W2010499248 hasIssue "3" @default.
• W2010499248 hasLocation W20104992481 @default.
• W2010499248 hasLocation W20104992482 @default.
• W2010499248 hasOpenAccess W2010499248 @default.
• W2010499248 hasPrimaryLocation W20104992481 @default.
• W2010499248 hasRelatedWork W1975657006 @default.
• W2010499248 hasRelatedWork W1992285201 @default.
• W2010499248 hasRelatedWork W1992782078 @default.
• W2010499248 hasRelatedWork W2088421588 @default.
• W2010499248 hasRelatedWork W2165147224 @default.
• W2010499248 hasRelatedWork W2226335814 @default.
• W2010499248 hasRelatedWork W2404099963 @default.
• W2010499248 hasRelatedWork W2463578927 @default.
• W2010499248 hasRelatedWork W2889516906 @default.
• W2010499248 hasRelatedWork W4366591216 @default.
• W2010499248 hasVolume "28" @default.
• W2010499248 isParatext "false" @default.
• W2010499248 isRetracted "false" @default.
• W2010499248 magId "2010499248" @default.
• W2010499248 workType "article" @default.